The 3D chromatin landscape of rhabdomyosarcoma

Meng Wang1, Prethish Sreenivas2, Benjamin D Sunkel1

  • 1Nationwide Children's Hospital, Center for Childhood Cancer, Columbus, OH 43205, USA.

NAR Cancer
|June 16, 2023
PubMed

Insights

This study reveals key 3D chromatin structures in pediatric rhabdomyosarcoma (RMS), a cancer lacking targeted therapies. Understanding these structures offers new avenues for precision medicine in fusion-positive and fusion-negative RMS.

Area of Science:

  • Genomics
  • Cancer Biology
  • Epigenetics

Background:

  • Rhabdomyosarcoma (RMS) is a pediatric soft tissue cancer with limited precision therapy options.
  • The genetic landscape of RMS is not fully understood, suggesting non-mutational drivers like chromatin structure may be crucial for tumor growth.

Purpose of the Study:

  • To define the 3D chromatin architecture in major subtypes of rhabdomyosarcoma (RMS).
  • To investigate the role of chromatin structural mechanisms in RMS proliferation.
  • To compare chromatin structures between cell lines and patient-derived xenografts (PDXs) across different RMS subtypes.

Main Methods:

  • High-depth in situ Hi-C experiments were performed on representative RMS cell lines and PDXs.
  • Chromatin interaction maps were generated and analyzed for fusion-positive RMS (FP-RMS) and fusion-negative RMS (FN-RMS).
  • Comparative analysis was conducted between cell line and PDX models.

Main Results:

  • Comprehensive 3D chromatin structural analysis was performed for FP-RMS and FN-RMS.
  • Common and distinct structural elements were identified in large megabase-scale chromatin compartments.
  • Variable topologically associating domains containing tumor-essential genes and unique structural variations were characterized.

Conclusions:

  • High-depth chromatin interactivity maps provide context for gene regulatory events in RMS.
  • The study reveals functional chromatin domains critical for RMS.
  • These findings lay the groundwork for understanding chromatin's role in RMS pathogenesis and developing precision therapies.